BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On December 19, 2025, as an inducement material to accept...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAYSEN Case No. 3:25-cv-02036-TLT STEVENSON, and CHRISTIAN JACOBSEN, (Shareholder Derivative Action) Derivatively on Behalf of CareDx, Inc., SUMMARY NOTICE OF PE...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the third manuscript from Surveillance HeartCare Outcomes Registry (SHORE) in the Jou...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences: Stephens Investment Co...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On November 4, 2025, as an inducement material ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data presentations featuring CareDx technologies at American Society of Ne...
CareDx, Inc ( CDNA ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Tina Jacobsen John Hanna - President, CEO & Director Nathan Smith - Chief Financial Officer Keith Kennedy - Chief Operating Officer Conference Call Participants Margarate Boeye - William Blair & Company L.L.C., Research Division Vidyun Bais - BTIG, LLC, Research Division William Bonello - Craig-Hallum C...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financia...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.